Skip to search formSkip to main contentSkip to account menu

INCB028050

Known as: INCB 028050 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

baricitinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis
Background LY3009104 (LY) is a novel, oral inhibitor of the JAK1/JAK2 signalling pathway known to be important in the… 
Review
2013
Review
2013
SP0169 JAK inhibition in patients with rheumatoid arthritis
The Janus Kinase (JAK) group of tyrosine kinases are intracellular signaling molecules which become phosphorylated upon… 
2010
2010
Preclinical Characterization of INCB 028050 Efficacious in Rodent Models of Arthritis : Selective Inhibition of JAK 1 and JAK 2 Is
Review
2010
Review
2010
Are Th17 Cells an Appropriate New Target in the Treatment of Rheumatoid Arthritis?
Th17 cells play crucial roles not only in host defense but also in many human autoimmune diseases and corresponding animal models… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)